Jerzy S. Pieczykolan

2A Ogrodowa Street
Lomianki, MZ 05092, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Development of Bispecific Antibody Targeting Human IL-17A and IL-6.

Development of Bispecific Antibody Targeting Human IL-17A and IL-6.

Journal: Antibodies (Basel, Switzerland)

Published: January 23, 2026

Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy.

Preclinical evaluation of CPL423: a novel potent small-molecule inhibitor of TAM family and FLT3 kinase for cancer therapy.

Journal: Frontiers in pharmacology

Published: December 15, 2025

Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation.

Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: October 31, 2025

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.

Journal: Molecular biomedicine

Published: July 20, 2025

Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson's disease and its comorbidities.

Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson's disease and its comorbidities.

Journal: The Journal of pharmacology and experimental therapeutics

Published: May 14, 2024

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.

Journal: Frontiers in oncology

Published: September 13, 2023

Identification and characterization of aptameric inhibitors of human neutrophil elastase.

Identification and characterization of aptameric inhibitors of human neutrophil elastase.

Journal: The Journal of biological chemistry

Published: October 24, 2022

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects.

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects.

Journal: Frontiers in pharmacology

Published: July 21, 2022

Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.

Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 22, 2022

Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy.

Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy.

Journal: Cancers

Published: April 22, 2022

Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study.

Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study.

Journal: Pulmonary pharmacology & therapeutics

Published: July 23, 2021

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

Journal: PloS one

Published: July 06, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026